Frazier Healthcare Partners — 2025 Investments
5 investments dated 2025 · listed companies and verified rows first · show all
Alesta Therapeutics develops therapies for rare diseases, with research focused on genetic diseases and oncology.
BiotechHealthtech
Ilan Ganot(CEO)inBenit Maru(CMO)Matthias Van Woensel(CSO)in
Co-investorsDroia VenturesFrazier Life SciencesNovartis Venture FundMPM BioImpactRTW Investments L.P.Thuja Capital
Iolyx is a pharmaceutical company focused on developing treatments for ocular conditions.
BiotechMedical Devices
Elizabeth Jeffords(CEO & President)inErin Newman(Chief Development Officer)inShannon Dahl(Chief Scientific Officer)inBryan Boyle(Chief Legal & Administrative Officer)in
Co-investorsFrazier Life Sciences
The page is a placeholder shell showing only cookie/consent notices for embedded third-party content (Vimeo, YouTube, reCAPTCHA, social media) and contains no substantive information about the company.
Dominik Schumacher(Founder)in
Co-investorsAndera PartnersBioMedPartnersFrazier Life SciencesFund+Nextech InvestOCCIDENT
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Callio TherapeuticsHillStar Bio
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.